ArticleBreast (Edinburgh, Scotland)2026

Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France.

JeanSebastien Frenel et al.PubMed ↗Publisher ↗

No numbers read from the abstract.